Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma

Hepato-Gastroenterology

Volumn 48, Issue 41, 2001, Pages 1493-1498

  Schwarz, R E ^a   Keny, H ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Perampullary Adenocarcinoma; Preperative platelet count; Resection; Survival

Indexed keywords

ADULT; AGED; ARTICLE; BILE DUCT CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; DUODENUM CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; MULTIVARIATE ANALYSIS; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PERIAMPULLARY ADENOCARCINOMA; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTHROMBIN TIME; SPLENECTOMY; SURVIVAL RATE; THROMBOCYTE COUNT;

ADENOCARCINOMA; AGED; AMPULLA OF VATER; COMMON BILE DUCT NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATECTOMY; PLATELET COUNT; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE;

EID: 0034776448     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. The thrombocytopenia of cancer. Prospects for effective cytokine therapy
2. Thrombocytosis and cancer. Apropos of a chronological series of 100 patients
3. Platelet count and survival in patients with colorectal cancer - A preliminary study
4. Prognostic significance of thrombocytosis in patients with primary lung cancer
5. Poor prognosis associated with thrombocytosis in patients with cervical cancer
6. The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer
7. Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival
8. Thrombocytosis as a prognostic factor in endometrial carcinoma
9. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B
10. Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
11. A prediction scoring system to select the surgical treatment of liver cancer. Further refinement based on 10 years of use
12. Natural killer cell activity in patients with hepatocellular carcinoma: A new prognostic indicator after hepatectomy
13. Can we predict very short term survival in small cell lung cancer?
14. Pancreatic carcinoma and Trousseau's syndrome: Experience at a large cancer center
15. Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines
16. Prevention of human pancreatic cancer cell-induced hepatic metastasis in nude mice by dipyridamole and its analog RA-233
17. Factors predicting hospitalization after operative treatment for gastric carcinoma in patients older than 70 years
18. Nonparametric estimation from incomplete observations
19. Asymptotically efficient rank invariant test procedures
20. Regression models and life tables
21. A mortality-free decade of pancreatoduodenectomy: Is quality independent of quantity?
22. Thrombocytosis in surgically treated stage IB squamous cell cervical carcinoma (A Gynecologic Oncology Group study)
23. Thrombocytosis as a prognostic factor in women with cervical cancer
24. Significance of thrombocytosis in patients with epithelial ovarian cancer
25. Hepatocyte volume as an indicator of hepatic functional reserve in cirrhotic patients with liver tumours
26. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?
27. Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure
28. The omnipotent platelet
29. Involvement of platelets in tumour angiogenesis?
30. Anemia and cancer
31. Platelet turnover in metastatic cancer and the effect of platelet aggregation inhibitors
32. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies
33. Hypersplenism in advanced breast cancer: Report of a patient treated with splenectomy
34. Splenectomy for hypersplenism in malignant lymphomas
35. The impact of splenectomy on outcomes after resection of pancreatic adenocarcinoma
36. Management of adenocarcinoma of the body and tail of the pancreas
37. Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease
38. Activation of cancer cell proteases and cytotoxicity by EGF and PDGF growth factors
39. Platelets as a source of growth-promoting factor(s) for tumor cells
40. Vascular endothelial growth factor platelet counts, and prognosis in renal cancer
41. Plasma thrombospondin levels in patients with colorectal carcinoma
42. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer
43. Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas
44. Platelet-derived growth factor (PDGF)-signaling mediates radiation- induced apoptosis in human prostate cancer cells with loss of p53 function
45. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1
46. Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer
47. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma
48. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies